

Seeking In Vivo and In Vitro Models Exhibiting Resistance to Immune Checkpoint Inhibitors

Daiichi Sankyo, a global pharmaceutical company, is seeking research on *in vivo* animal models and *in vitro* cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors (ICIs).



Approaches of Interest:

- The **mechanism of resistance** (MoR) is **clearly defined** and is tumor-intrinsic
- The **PD-1 and PD-L1 immune checkpoint pathways** are of highest interest
- Research focused on **solid tumors** (lung, breast and pancreatic tumors are of primary interest)
- The MoR to ICI reflects clinical observations
- The MoR to ICI is associated with specific patient selection biomarker

Out of Scope:

- Submissions relating to blood cancers
- Opportunities that lack a clear MoR or have tumor-extrinsic MoR

Developmental Stages of Interest:

- Opportunities from basic research to registration are in scope providing there is a clear MoR

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. **Our client is also open to novel research proposals which can be outlined using this [submission form](#)**. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Academics and expertise
-  Technologies
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **19th January 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk